Company / R&D Expense
Sonoma Pharmaceuticals, Inc. R&D Expense History
FY2017-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.8M
FY2026
5-year range
$125.0K / $1.9M
FY2022-FY2026
Trend
-3.0%
vs FY2025
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $207,000 to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2026 with a 5-year CAGR of +6.3%.
Improved from $207,000 to $2M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +143.9%
- 5-Year CAGR
- +6.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +6.3%, indicating consistent growth.
- In FY2026, r&d expense decreased 3.0% year-over-year.
- Peak r&d expense was recorded in FY2025.
- Lowest r&d expense in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2026 | $1.8M | -3.0% |
| FY2025 | $1.9M | +803.9% |
| FY2024 | $207.0K | +65.6% |
| FY2023 | $125.0K | -77.5% |
| FY2022 | $555.0K | -58.6% |
| FY2021 | $1.3M | -11.8% |
| FY2020 | $1.5M | -3.6% |
| FY2019 | $1.6M | -0.1% |
| FY2018 | $1.6M | -12.7% |
| FY2017 | $1.8M | +17.8% |
As of FY2026 · SEC 10-K · Updated Jun 28, 2026